JP2014511393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511393A5 JP2014511393A5 JP2013557763A JP2013557763A JP2014511393A5 JP 2014511393 A5 JP2014511393 A5 JP 2014511393A5 JP 2013557763 A JP2013557763 A JP 2013557763A JP 2013557763 A JP2013557763 A JP 2013557763A JP 2014511393 A5 JP2014511393 A5 JP 2014511393A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- effective amount
- therapeutically effective
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 24
- 239000013543 active substance Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 3
- -1 3-ethoxy-4-methoxyphenyl Chemical group 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229960002986 dinoprostone Drugs 0.000 claims 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 125000002575 PGE2 group Chemical group 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000000091 immunopotentiator Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449716P | 2011-03-07 | 2011-03-07 | |
| US61/449,716 | 2011-03-07 | ||
| PCT/US2012/027368 WO2012121988A2 (en) | 2011-03-07 | 2012-03-02 | Methods for treating diseases using isoindoline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014511393A JP2014511393A (ja) | 2014-05-15 |
| JP2014511393A5 true JP2014511393A5 (enExample) | 2015-04-16 |
Family
ID=45852726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557763A Pending JP2014511393A (ja) | 2011-03-07 | 2012-03-02 | イソインドリン化合物を用いた疾患の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9387195B2 (enExample) |
| EP (2) | EP2683376B1 (enExample) |
| JP (1) | JP2014511393A (enExample) |
| ES (2) | ES2711100T3 (enExample) |
| WO (1) | WO2012121988A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2884454C (en) * | 2012-10-11 | 2021-07-27 | Nerre Therapeutics Limited | Orvepitant and uses thereof |
| EP3010490A1 (en) * | 2013-06-17 | 2016-04-27 | Celgene Corporation | Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| RU2538615C1 (ru) * | 2013-08-20 | 2015-01-10 | Общество с ограниченной ответственностью "УНИФАРМ" (ООО "УНИФАРМ"). | Средство для профилактики и лечения простатита и аденомы предстательной железы |
| CN105669478A (zh) * | 2014-11-17 | 2016-06-15 | 重庆医药工业研究院有限责任公司 | 一种制备3-氨基邻苯二甲酸及其衍生物的方法 |
| AU2015371308A1 (en) | 2014-12-23 | 2017-08-03 | Intellectual Property Associates, Llc | Methods and formulations for transdermal administration |
| WO2017085568A1 (en) * | 2015-11-19 | 2017-05-26 | Alembic Pharmaceuticals Limited | An improved process and novel polymorphic form of apremilast |
| CN105388237B (zh) * | 2015-12-28 | 2017-02-01 | 成都百裕金阁莱药业有限公司 | 阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法 |
| EP3435973B1 (en) * | 2016-03-30 | 2023-11-01 | Sarudbhava Formulations Private Limited | Apremilast pharmaceutical compositions |
| JP6827113B2 (ja) * | 2017-01-21 | 2021-02-10 | 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． | シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用 |
| US20190374508A1 (en) * | 2017-01-27 | 2019-12-12 | Sarudbhava Formulations Private Limited | Therapeutic topical compositions of apremilast |
| JP2020534285A (ja) | 2017-09-15 | 2020-11-26 | アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 投与および処置の方法 |
| US20240252426A1 (en) * | 2018-09-21 | 2024-08-01 | Apramitha Innovations Private Limited | Improved and stable apremilast pharmaceutical compositions |
| BR112021013174A2 (pt) | 2019-01-11 | 2021-11-03 | Novartis Ag | Anticorpos anti-cd40 para uso no tratamento da hidradenite supurativa |
| CN115068406A (zh) * | 2021-03-12 | 2022-09-20 | 浙江万晟药业有限公司 | 一种用于治疗斑秃的阿普斯特凝胶及其制备工艺 |
| WO2023120466A1 (ja) * | 2021-12-23 | 2023-06-29 | 沢井製薬株式会社 | アプレミラスト水和物含有製剤 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| US7893101B2 (en) * | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| HUE039709T2 (hu) | 2002-05-28 | 2019-01-28 | Astrazeneca Ab | Helyileg alkalmazandó gyógyászati készítmény |
| CN101745112A (zh) | 2002-07-19 | 2010-06-23 | 艾博特生物技术有限公司 | TNFα相关疾病的治疗 |
| BR0314783A (pt) * | 2002-09-27 | 2005-07-26 | Janssen Pharmaceutica Nv | Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias |
| CN1984651A (zh) | 2004-05-05 | 2007-06-20 | 细胞基因公司 | 使用选择性细胞因子抑制药治疗和控制癌症和其它疾病的方法和组合物 |
| DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| BRPI0519030A2 (pt) | 2004-12-13 | 2008-12-23 | Celgene Corp | mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica |
| US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| WO2008013791A2 (en) * | 2006-07-24 | 2008-01-31 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
| ES2380395T3 (es) * | 2007-04-16 | 2012-05-11 | Leo Pharma A/S | Triazolopiridinas como inhibidores de fosfodiesterasa para el tratamiento de enfermedades dérmicas |
| CN102046167A (zh) * | 2008-03-27 | 2011-05-04 | 细胞基因公司 | 包含(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰基氨基异吲哚啉-1,3-二酮的固体形式、其组合物及其用途 |
| BRPI0922452A2 (pt) * | 2008-12-19 | 2015-12-15 | Leo Pharma As | composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos. |
| EP2805746B1 (en) * | 2009-02-16 | 2020-05-06 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
| CA2766967A1 (en) * | 2009-06-30 | 2011-01-06 | Piramal Life Sciences Limited | Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation |
| EP2498753B1 (en) * | 2009-11-10 | 2019-03-06 | Celgene Corporation | Nanosuspension of a poorly soluble drug made by microfluidization process |
-
2012
- 2012-03-02 ES ES12709437T patent/ES2711100T3/es active Active
- 2012-03-02 EP EP12709437.3A patent/EP2683376B1/en active Active
- 2012-03-02 WO PCT/US2012/027368 patent/WO2012121988A2/en not_active Ceased
- 2012-03-02 ES ES17208060T patent/ES2868231T3/es active Active
- 2012-03-02 JP JP2013557763A patent/JP2014511393A/ja active Pending
- 2012-03-02 US US14/003,750 patent/US9387195B2/en active Active
- 2012-03-02 EP EP17208060.8A patent/EP3320902B1/en not_active Revoked
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511393A5 (enExample) | ||
| JP2016540738A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| JP2009522289A5 (enExample) | ||
| JP2013155188A5 (enExample) | ||
| WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
| HRP20211644T1 (hr) | Liječenje ili prevencija kardiovaskularnih događaja administracijom kolhicina | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2012515184A5 (enExample) | ||
| FI3865484T3 (fi) | Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon | |
| JP2012193216A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| WO2015034678A3 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| JP2013540766A5 (enExample) | ||
| JP2015515985A5 (enExample) | ||
| JP2013538853A5 (enExample) | ||
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| JP2015537009A5 (enExample) | ||
| ME02474B (me) | Terapijski režimi | |
| JP2019530706A5 (enExample) | ||
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| EP2606887A4 (en) | DIINDOLYLMETHANE AND PRECURSORS AND DERIVATIVES THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LIVER DISEASES | |
| PH12019500516A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| FI3302451T3 (fi) | Palmitoyylietanoliamidia (pea) ja lykopeenia sisältävä yhdistelmä käytettäväksi inflammatoristen sairauksien hoidossa | |
| EA201101622A1 (ru) | Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования |